Influvac Tetra (B/Phuket/3073/2013-Like Virus (B/Phuket/3073/2013, Wild Type), Influenza Virus B/Austria/1359417/202)

The vaccine contains purified, inactivated whole‑virus particles from four influenza strains. After injection, the viral antigens are processed by the immune system, prompting B‑cell activation and the generation of strain‑specific neutralising antibodies. This active immunity enables the body to recognise and neutralise matching influenza viruses upon future exposure.

The prescribed dose of Influvac Tetra is determined by a qualified healthcare professional. Typically, a single intramuscular or subcutaneous injection is given each influenza season, but the exact volume and administration schedule are set by the prescriber based on age, health status and local immunisation guidelines.

Data on the use of Influvac Tetra in pregnant or lactating individuals are limited. Healthcare providers should evaluate the potential benefits against any theoretical risks. In many regions, inactivated influenza vaccines are considered acceptable during pregnancy when the benefit of protecting the mother and fetus outweighs uncertainties.

To order Influvac Tetra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Influvac Tetra is a quadrivalent, inactivated vaccine that covers two influenza A subtypes and both B lineages, offering broader protection than trivalent formulations. Unlike live‑attenuated nasal sprays, it is administered by injection and is suitable for a wider range of age groups, including immunocompromised patients, due to its non‑replicating nature.

The vaccine must be stored refrigerated at 2‑8 °C. It should be kept in the original packaging to protect from light, must not be frozen, and should not be shaken. Prior to administration, allow the vial to reach room temperature for a short period if required by local practice.

Influvac Tetra is supplied as a sterile injectable solution. It is given by a single intramuscular or subcutaneous injection, usually into the deltoid muscle of the upper arm for adults or the anterolateral thigh for infants and young children, following aseptic technique and standard vaccination procedures.

The most serious adverse events reported are severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and high‑grade fever or seizures. These events are rare but require immediate medical attention. Recipients should be observed for at least 15 minutes after injection to detect any early signs of a serious reaction.

Influvac Tetra should not be administered to individuals with a known severe allergy to any component of the vaccine or to those who have experienced a previous anaphylactic reaction to an influenza vaccine. It is also contraindicated in persons with active, moderate or severe acute illness until they have recovered.